PERRY GREGORY D

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 11

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,500 shares

Expires 2029-06-12

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 10

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 4,983 shares

Expires 2028-07-20

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 9

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,650 shares

Expires 2027-05-24

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 8

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 17,000 shares

Expires 2026-05-18

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 7

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,631 shares

Expires 2030-06-30

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 6

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,120 shares

Expires 2031-05-28

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 5

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 16,604 shares

Expires 2032-05-31

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 4

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 14,414 shares

Expires 2033-06-08

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 3

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 372,924 shares

Expires 2033-06-14

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 2

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 107,300 shares

Expires 2034-01-31

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001193125-25-317968 · ownership.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 100,000 shares

Expires 2035-01-29

F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

SEC source: 0001415889-25-017613 · form4-06172025_080606.xml · derivative · entry 2

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,450

Underlying: Common Stock · 5,450 shares

Expires 2035-06-14

F3 · derivative.exercise_date: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

SEC source: 0001415889-25-017613 · form4-06172025_080606.xml · nonDerivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,344

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

F2 · balance_after: Includes 6,355 unvested RSUs.

SEC source: 0000950170-25-011795 · ownership.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Shares · 100,000 shares

Expires 2035-01-29

F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2025. 25% vest on January 1, 2026 and in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-016572 · form4-06122024_080609.xml · derivative · entry 2

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,150

Underlying: Common Stock · 3,150 shares

Expires 2034-06-10

F3 · derivative.exercise_date: This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.

SEC source: 0001415889-24-016572 · form4-06122024_080609.xml · nonDerivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,894

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.

F2 · balance_after: Includes 8,525 unvested RSUs.

SEC source: 0000950170-24-057092 · ownership.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer & PFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,300

Underlying: Common Shares · 107,300 shares

Expires 2034-01-31

F1 · date: On February 1, 2024, the Board of Directors approved the grant of options to purchase the common shares, at an exercise price of $36.09 per share, subject to the Company's general meeting resolving upon, and the Board having implemented through an amendment to the Company's articles of association, an increase in the authorized share capital sufficient to satisfy the award set forth (the "Shareholder Approval Condition"). On May 7, 2024, the shareholders approved the amendment to the Company's articles of association, including the increase in the authorized share capital satisfying the Shareholder Approval Condition.

F2 · derivative.exercise_date: Options vest over a four-year period from January 1, 2024. 25% vest on January 1, 2025 and in 36 equal monthly installments thereafter.

SEC source: 0001415889-23-010290 · form4-06232023_080622.xml · derivative · entry 4

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2033-06-21

F6 · derivative.exercise_date: This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.

SEC source: 0001415889-23-010290 · form4-06232023_080622.xml · derivative · entry 3

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,808

Underlying: Common Stock · 7,808 shares

Expires 2033-06-21

F5 · derivative.exercise_date: This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

SEC source: 0001415889-23-010290 · form4-06232023_080622.xml · nonDerivative · entry 2

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,494

F3 · security: Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.

F4 · balance_after: Includes 9,494 unvested RSUs.

SEC source: 0001415889-23-010290 · form4-06232023_080622.xml · nonDerivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,394

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.

F2 · balance_after: Includes 8,394 unvested RSUs.

SEC source: 0001209191-23-037340 · doc4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 372,924

Underlying: Common Shares · 372,924 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on the first anniversary of the date of grant, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter, such that the options shall be vested and exercisable as to all shares on the fourth anniversary of the date of grant, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date.

SEC source: 0001209191-23-036264 · doc4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,414

Underlying: Common Shares · 14,414 shares

Expires 2033-06-08

F1 · derivative.exercise_date: Options vest over a one-year period commencing June 8, 2023 in 12 equal monthly installments.

SEC source: 0001415889-23-009142 · form4-06022023_080638.xml · derivative · entry 4

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 800 shares

Expires 2032-06-15

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 938 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 800 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F6 · derivative.exercise_date: The cancelled option was granted on June 16, 2022 and provided for vesting as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-009142 · form4-06022023_080638.xml · derivative · entry 3

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 420 shares

Expires 2029-06-04

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 938 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 800 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F5 · derivative.exercise_date: The cancelled option was granted on June 5, 2019 and provided for vesting with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-009142 · form4-06022023_080638.xml · derivative · entry 2

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 518 shares

Expires 2028-02-28

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 938 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 800 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: The cancelled option was granted on February 28, 2018 and provided for vesting with respect to 1/3rd of the shares on the first anniversary of the grant and with respect to an additional 1/36th of the shares on each monthly anniversary thereafter and was subject to vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-009142 · form4-06022023_080638.xml · nonDerivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,538

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 938 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 800 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F2 · balance_after: Includes 2,538 unvested or deferred RSUs.

SEC source: 0001415889-22-006751 · form4-06172022_040613.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

SEC source: 0000899243-22-020665 · doc4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,604

Underlying: Common Shares · 16,604 shares

Expires 2032-05-31

F1 · derivative.exercise_date: Options vest over a one-year period commencing May 31, 2022 in 12 equal monthly installments.

SEC source: 0001209191-22-013770 · doc4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-02-24

F1 · derivative.exercise_date: This option vests in equal monthly installments over a four-year period commencing on February 1, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

SEC source: 0001415889-21-003123 · form4-06212021_050627.xml · nonDerivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021.

F2 · balance_after: Includes 20,000 unvested RSUs.

SEC source: 0000899243-21-021544 · doc4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,120

Underlying: Common Shares · 6,120 shares

Expires 2031-05-28

F1 · derivative.exercise_date: Options vest over a one-year period commencing May 28, 2021 in 12 equal monthly installments.

SEC source: 0001209191-21-021961 · doc4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,386

Underlying: Common Stock · 55,386 shares

Expires 2031-03-17

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 18, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-20-040201 · doc4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,631

Underlying: Common Shares · 8,631 shares

Expires 2030-06-30

F1 · derivative.exercise_date: Options vest over a one-year period commencing June 30, 2020 in 12 equal monthly installments.

SEC source: 0001104659-20-078327 · a4.xml · nonDerivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 25, 2021 or (ii) the date of the first annual meeting following June 25, 2020.

F2 · balance_after: Includes 20,000 unvested RSUs.

SEC source: 0001104659-19-034524 · a4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2029-06-04

F1 · derivative.exercise_date: This option was granted on June 5, 2019 and vests with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter.

SEC source: 0001179110-18-003330 · edgar.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,920

Underlying: Common Stock · 25,920 shares

Expires 2028-02-28

F1 · derivative.exercise_date: This option was granted on February 28, 2018 and vests with respect to 1/3 of the shares on the first anniversary of the grant and with respect to an additional 1/36th of the shares on each monthly anniversary thereafter and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001104659-17-031893 · a4.xml · derivative · entry 3

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,786

Underlying: Common Shares · 2,393 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share.

F1 · shares: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.

F4 · derivative.exercise_date: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019.

F4 · derivative.expiration_date: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019.

F1 · derivative.underlying_shares: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.

F1 · balance_after: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.

SEC source: 0001104659-17-031893 · a4.xml · nonDerivative · entry 2

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,683

F3 · shares: The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person.

SEC source: 0001104659-17-031893 · a4.xml · nonDerivative · entry 1

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.

F2 · price: Each restricted stock unit represents a contingent right to receive one common share.

F1 · balance_after: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.

SEC source: 0001104659-16-163878 · a4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,020

Underlying: Common Shares · 166,020 shares

Expires 2026-12-22

F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.

F2 · derivative.exercise_date: The common shares underlying this stock option award will vest in three equal installments on December 22, 2017, December 22, 2018 and December 22, 2019, respectively, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates.

SEC source: 0001104659-16-159833 · a4.xml · derivative · entry 5

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires not disclosed

F6 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of common stock.

F8 · price: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger.

F7 · derivative.exercise_date: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

F7 · derivative.expiration_date: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

SEC source: 0001104659-16-159833 · a4.xml · derivative · entry 4

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 69,000 shares

Expires 2026-05-09

F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion").

F5 · derivative.exercise_date: 25% of the shares of common stock underlying this stock option award were to vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

SEC source: 0001104659-16-159833 · a4.xml · derivative · entry 3

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires 2026-02-12

F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion").

F4 · derivative.exercise_date: 25% of the shares of common stock underlying this stock option award vested on February 12, 2016. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in three equal installments on each of December 31, 2016, December 31, 2017 and December 31, 2018, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

SEC source: 0001104659-16-159833 · a4.xml · derivative · entry 2

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2025-08-04

F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion").

F3 · derivative.exercise_date: 25% of the shares of common stock underlying this stock option award vested on August 4, 2016. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through August 4, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

SEC source: 0001104659-16-159833 · a4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires 2025-08-03

F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion").

F1 · derivative.exercise_date: 25% of the shares of common stock underlying this stock option award vested on August 3, 2016. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through August 3, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

SEC source: 0001104659-16-160113 · a4.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,896

Underlying: Common Shares · 35,896 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of the Issuer.

F3 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, Aegerion Pharmaceuticals, Inc. ("Aegerion") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into Aegerion, effective on November 29, 2016, each restricted stock unit with respect to common stock of Aegerion ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit with respect to a number of common shares of the Issuer ("Issuer RSU") equal to the product obtained by multiplying (i) the total number of shares of common stock of Aegerion subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the exchange ratio of 1.0256.

F4 · price: Each Issuer RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger.

F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018 and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries.

F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018 and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries.